Skip to main content

Lawrence Kurzius

Equibles does not estimate personal net worth.

Get an email with a short summary when Elanco Animal Health Inc publishes a filing, an earnings call transcript or a press release.

Get ELAN alerts

About Lawrence Kurzius

Lawrence Kurzius is recorded as Board Member at Elanco Animal Health Inc (ELAN) since May 30, 2024. The newest filing on record that lists Lawrence Kurzius as Board Member at Elanco Animal Health Inc (ELAN) is dated April 8, 2026. Earlier roles on record: Chairman at Mccormick & Co Inc (MKC) until December 31, 2024. Elanco Animal Health Inc reported in an 8-K filed June 4, 2024 that Lawrence Kurzius was appointed member of the Board, effective May 30, 2024. The proxy statement of Mccormick & Co Inc reports total compensation of $6,657,928 for Lawrence Kurzius in fiscal 2024, including a base salary of $1,298,077. Disclosed compensation is on record for 8 fiscal years. Lawrence Kurzius has spoken on 13 earnings calls across 1 company, most recently for Mccormick & Co Inc on June 29, 2023. Elanco Animal Health Inc is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other companies whose calls Lawrence Kurzius spoke on are classified in the Consumer Defensive sector. Other leadership on record at Elanco Animal Health Inc includes Jeffrey N. Simmons (CEO and Board Member), Jeffrey Simmons (CEO and Board Member), Robert (Bob) VanHimbergen (CFO) and 7 others.

“the Board reappointed Ms. Turner to the Board as a member of the 2025 class and Mr. Kurzius to the Board as a member of the 2026 class, in all cases effective immediately upon completion of the Company’s annual meeting of shareholders on May 30, 2024 (the “2024 Annual Meeting”) and with Ms. Turner’s and Mr. Kurzius’ service on the Board deemed to have continued uninterrupted.”
Elanco Animal Health Inc Form 8-K, filed June 4, 2024 · Read the filing

Lawrence Kurzius on recent calls

“To start, last night, we announced that Brendan Foley will become McCormick’s next Chief Executive Officer on September 1, and he is joining the Board of Directors immediately.”
Chairman, Mccormick & Co Inc Q2 FY2023 Earnings Call ·
“We are pleased with the start of the year. We delivered solid first quarter results that reflect strong demand and early results from our actions to increase our profit realization in 2023.”
Chairman, Mccormick & Co Inc Q1 FY2023 Earnings Call ·
“Our fourth quarter concluded a challenging and volatile year that impacted our ability to deliver on our expectations and our financial performance.”
Chairman, Mccormick & Co Inc Q4 FY2022 Earnings Call ·
“Third quarter sales increased 3% from the year-ago period as anticipated.”
Chairman, Mccormick & Co Inc Q3 FY2022 Earnings Call ·
“I'd like to start by welcoming Brendan to this morning's call. In addition to his continuing role as President of our Global Consumer business, Brendan now has responsibility for our business worldwide in his newly appointed role as President and COO.”
Chairman, Mccormick & Co Inc Q2 FY2022 Earnings Call ·

Affiliation history

Company network

Current role

Drug Manufacturers - Specialty & Generic · Healthcare

Board Member

2018-01-01–present

Leadership on record at Elanco Animal Health Inc

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2024 Mccormick & Co Inc (MKC) $1,298,077 $6,657,928
2023 Mccormick & Co Inc (MKC) $1,250,000 $12,602,133
2022 Mccormick & Co Inc (MKC) $1,250,000 $10,426,035
2021 Mccormick & Co Inc (MKC) $1,250,000 $12,718,656
2020 Mccormick & Co Inc (MKC) $1,250,000 $19,546,334
2019 Mccormick & Co Inc (MKC) $1,250,000 $12,769,184
2018 Mccormick & Co Inc (MKC) $1,163,462 $14,836,426
2017 Mccormick & Co Inc (MKC) $965,385 $9,048,299

Recent activity